-+ 0.00%
-+ 0.00%
-+ 0.00%
Lufax Holding (NYSE:LU) Stock Sinks As Q3 Results Deepen Credit Losses
Share
Listen to the news

Lufax Holding just reported Q3 2026 and the stock dropped 3.9% to $8.17. On the screen it looks like another bad day for a lender already under pressure, with the share price also down sharply over the past month and quarter. The headline inside the release is a deep net loss of RMB 1,494m, driven by heavier credit impairment charges and a sizeable tax hit.

That sounds ugly in the near term. For anyone thinking beyond today, the key issue is the growing strain on profitability and what that means for a business trading on a low price to sales multiple compared with consumer finance peers.

Concerned that Lufax Holding is absorbing heavy credit losses while trading on a low P/S multiple? Compare this setup with a curated list of lenders and financials that pair disciplined balance sheets with stronger fundamentals in our list of solid balance sheet and fundamentals stocks (24 results)

Q3 2026 Earnings Summary

  • Total Revenue (Q3 2026 vs Q3 2025): RMB 6,179.7m vs. RMB 7,955.0m (declined 22.3%)
  • Net Income/Loss (Excl. Extra Items, Q3 2026 vs Q3 2025): loss of RMB 1,535.4m vs. loss of RMB 665.2m (loss widened 130.8%)
  • Basic EPS (Q3 2026 vs Q3 2025): loss of RMB 17.8 per share vs. loss of RMB 7.68 per share (loss per share worsened 131.7%)
  • Trailing 12-Month Total Revenue (Q3 2026 TTM vs Q3 2025 TTM): RMB 28,099.8m vs. RMB 32,825.8m (fell 14.4%)

Lufax took a big hit on credit losses and tax this quarter. Ask Charlie what Lufax’s AI push means for future losses.

NYSE:LU Trailing 12-Month Earnings & Revenue History as at Oct 2026
NYSE:LU Trailing 12-Month Earnings & Revenue History as at Oct 2026

Lufax Bull Case Hinges On Quality Shift, Not Yet Earnings

The bullish story hinges on Lufax Holding upgrading its borrower mix and allowing that to feed through to profitability over time.

"The push to grow mid to low risk customers across small business owners, individually owned businesses and salaried employees is designed to shift the book toward higher quality borrowers, which can support more resilient revenue and a path toward stronger earnings."

Loan mix is moving in that direction. New loan sales grew 2.5% year on year, with consumer finance up 25.2% and outstanding consumer balances up 19.8%. Funding costs fell, which supports this view. However, heavy credit impairment losses of RMB 4,511m and a widened net loss of RMB 1,494m indicate that any earnings benefit from this cleaner book has not yet appeared in the income statement.

The price and this Narrative do not agree. → Uncover what this Narrative says Lufax Holding is actually worth.

Lufax Bear Case: Earnings Reset Still Biting

The skeptical view argues that Lufax risks trading profitability for safer borrowers and heavier guarantees while credit costs stay high.

"The long term shift towards lower risk borrowers and a full guarantee model may improve asset quality for new vintages. However, it also concentrates more credit risk on Lufax Holding's own balance sheet and occurs while credit costs remain elevated relative to income, which could delay a sustained improvement in net margins and profitability."

Q3 results lean toward this concern. New loan sales rose and funding costs eased, yet credit impairment losses of RMB 4,511m and a RMB 1,494m net loss show margins still under strain, with the share price down over the past quarter, reinforcing that the earnings reset remains unresolved.

Hunt For Mispriced Earnings Power

Lufax Holding just reminded you how quickly a weak quarter can reset expectations. The real opportunity is finding stocks that could be undervalued before the market corrects them.

  • Company 1 - 26% below our estimate - targets utility and aerospace customers replacing aging grids with more digital, diagnostic heavy infrastructure.
  • Company 2 - 40% below our estimate - leans into coconut beverages as retailers expand shelf space for branded and private label options.
  • Company 3 - 25% below our estimate - builds out manufacturing capacity so cardiometabolic and obesity treatments can reach larger patient populations.

Three companies from the same screener. Open every one of the 29 undervalued companies on it →

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending